[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Maruyama K, Morita A, Shibahara J, Nakazato Y, Kirino T: Multifocal pilocytic astrocytomas with ependymal differentiation in the bilateral medial temporal lobes: case report. Neurol Med Chir (Tokyo); 2005 Aug;45(8):411-4
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal pilocytic astrocytomas with ependymal differentiation in the bilateral medial temporal lobes: case report.
  • The histological diagnosis was pilocytic astrocytoma with ependymal differentiation and a MIB-1 staining index of up to 8.0%.
  • Adjuvant chemotherapy consisting of carboplatin and vincristine was given followed by radiotherapy.
  • Neuroimaging showed that the bilateral tumors had disappeared and showed no recurrence for 29 months after the diagnosis.
  • Pilocytic astrocytoma usually presents as a solitary mass in the cerebellum or optic pathway with low proliferative activity, but should be included in the differential diagnosis of multifocal tumors arising in the bilateral temporal lobes.
  • Intensive treatment is recommended for patients with such specific neuroimaging and histological features.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Temporal Lobe / pathology
  • [MeSH-minor] Antibodies, Antinuclear. Antibodies, Monoclonal. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Proliferation. Child. Diagnosis, Differential. Ependyma / pathology. Hemianopsia / etiology. Hemianopsia / pathology. Hemianopsia / physiopathology. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neurosurgical Procedures. Paresis / etiology. Paresis / pathology. Paresis / physiopathology. Radiotherapy. Seizures / etiology. Seizures / pathology. Seizures / physiopathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127260.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / MIB-1 antibody
  •  go-up   go-down


2. Tsugu H, Oshiro S, Yanai F, Komatsu F, Abe H, Fukushima T, Nomura Y, Matsumoto S, Nabeshima K, Takano K, Utsunomiya H: Management of pilomyxoid astrocytomas: our experience. Anticancer Res; 2009 Mar;29(3):919-26
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pilomyxoid astrocytoma (PMA) shows a higher rate of recurrence and cerebrospinal fluid (CSF) dissemination than does pilocytic astrocytoma (PA).
  • In this article, we discuss the treatment of PMA.
  • All patients received chemotherapy; the most commonly used combination drugs were cisplatin (CDDP)/carboplatin (CBDCA) and etoposide.
  • When these drugs were unsuccessful, they were changed or other drugs added to the combination.
  • After chemotherapy, four patients showed remarkable tumor regression.
  • Nevertheless, one patient died 22 months after initial diagnosis, due to tumor progression.
  • CONCLUSION: While our series was limited to a small number of patients, we have a positive impression of the value of chemotherapy.
  • Even if initial chemotherapy is ineffective, we recommend continued CDDP/CBDCA-based chemotherapy with new drug combinations.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414328.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


3. Hukin J, Siffert J, Velasquez L, Zagzag D, Allen J: Leptomeningeal dissemination in children with progressive low-grade neuroepithelial tumors. Neuro Oncol; 2002 10;4(4):253-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Satisfactorily followed data were obtained on 427 of the 588 patients with localized LGN at diagnosis between 1986 and 1998, 177 (42%) of whom developed progressive or recurrent disease.
  • The median age at initial diagnosis was 5 years and at LM diagnosis was 8.5 years.
  • The histologies were pilocytic astrocytoma (4), ganglioglioma (4), fibrillary astrocytoma (3), mixed glioma (1), and glioneurofibroma (1).
  • Management included chemotherapy (2) or radiotherapy (3) or both (7); 1 patient received only radical resections of symptomatic lesions.
  • We strongly urge that for optimum treatment planning all patients with recurrent LGN be staged with an enhanced spine and brain MRI before adjuvant therapy is initiated.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / therapy. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12356355.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1920666
  •  go-up   go-down


Advertisement
4. Bohner G, Masuhr F, Distl R, Katchanov J, Klingebiel R, Zschenderlein R, von Deimling A, van Landeghem FK: Pilocytic astrocytoma presenting as primary diffuse leptomeningeal gliomatosis: report of a unique case and review of the literature. Acta Neuropathol; 2005 Sep;110(3):306-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilocytic astrocytoma presenting as primary diffuse leptomeningeal gliomatosis: report of a unique case and review of the literature.
  • Spinal leptomeningeal biopsy revealed a pilocytic astrocytoma WHO grade I.
  • Despite chemotherapy with vincristin and carboplatin, the patient died 2 months after admission.
  • A thorough autopsy showed no evidence for primary neoplasms in brain, spine and optic nerve.
  • Sequence analysis of tumor protein 53 gene (TP53) revealed a missense mutation in exon 5, and expression of phosphatase and tensin homolog (mutated in multiple advanced cancers 1) (PTEN) protein was not detected, which may have contributed to astrocytoma development.
  • To our knowledge, this is the first definitive case of pilocytic astrocytoma presenting as PDLG.
  • [MeSH-major] Astrocytoma / pathology. Meningeal Neoplasms / pathology. Meninges / pathology. Neoplasms, Neuroepithelial / pathology. Neoplasms, Unknown Primary / pathology. Subarachnoid Space / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / genetics. Brain / pathology. Brain / physiopathology. Diagnosis, Differential. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Mutation / genetics. Spinal Cord / pathology. Spinal Cord / physiopathology. Spinal Cord Compression / etiology. Spinal Cord Compression / pathology. Spinal Cord Compression / physiopathology. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Diffuse Astrocytoma.
  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16003541.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


5. Karami KJ, Poulik J, Rabah R, Krass J, Sood S: Simultaneous choroid plexus carcinoma and pilocytic astrocytoma in a pediatric patient. J Neurosurg Pediatr; 2010 Jan;5(1):104-12
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous choroid plexus carcinoma and pilocytic astrocytoma in a pediatric patient.
  • Simultaneous primary brain tumors in pediatric patients without prior chemotherapy or radiotherapy, phacomatosis, or known familial history are a rare occurrence.
  • The authors report the case of a 4-year-old boy with simultaneous choroid plexus carcinoma and pilocytic astrocytoma with features of oligodendroglioma.
  • Upon gross inspection intraoperatively as well as postoperative histological analysis, 2 distinct simultaneous tumors were identified: choroid plexus carcinoma and pilocytic astrocytoma.
  • To the authors' knowledge this is the first case report published identifying 2 distinct tumor types with similar radiological appearances in a pediatric patient with no prior history of radiotherapy, chemotherapy, or phacomatosis.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / surgery. Cerebral Ventricle Neoplasms / diagnosis. Cerebral Ventricle Neoplasms / surgery. Choroid Plexus Neoplasms / diagnosis. Choroid Plexus Neoplasms / surgery. Fourth Ventricle / surgery. Lateral Ventricles / surgery. Magnetic Resonance Imaging. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / surgery. Neuronavigation. Thalamus / surgery. Tomography, X-Ray Computed


6. Aarsen FK, Paquier PF, Arts WF, Van Veelen ML, Michiels E, Lequin M, Catsman-Berrevoets CE: Cognitive deficits and predictors 3 years after diagnosis of a pilocytic astrocytoma in childhood. J Clin Oncol; 2009 Jul 20;27(21):3526-32
MedlinePlus Health Information. consumer health - Hydrocephalus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cognitive deficits and predictors 3 years after diagnosis of a pilocytic astrocytoma in childhood.
  • PURPOSE To prospectively study cognitive deficits and predictors 3 years after diagnosis in a large series of pediatric patients treated for pilocytic astrocytoma (PA).
  • Included predictors were sex, age, relapse, diagnosis-assessment interval, hydrocephalus, kind of treatment, and tumor variables.
  • Predictors for lower cognitive functioning were hydrocephalus, radiotherapy, residual tumor size, and age; predictors for better functioning were chemotherapy or treatment of hydrocephalus.
  • Almost 60% of children had problems with academic achievement, for which risk factors were relapse and younger age at diagnosis.
  • Adequate treatment of hydrocephalus is important for a more favorable long-term cognitive outcome.
  • Even children without initial severe deficits may develop cognitive impairments years after diagnosis, partly because of the phenomenon of growing into deficit, which has devastating implications for academic achievement and quality of life (QOL).
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Cerebellar Neoplasms / complications. Cognition Disorders / etiology. Hydrocephalus / etiology

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433687.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Moshel YA, Elliott RE, Monoky DJ, Wisoff JH: Role of diffusion tensor imaging in resection of thalamic juvenile pilocytic astrocytoma. J Neurosurg Pediatr; 2009 Dec;4(6):495-505
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of diffusion tensor imaging in resection of thalamic juvenile pilocytic astrocytoma.
  • OBJECT: The choice of surgical approach during resection of a thalamic juvenile pilocytic astrocytoma (JPA) is dictated by the location of the displaced normal thalamus and posterior limb of the internal capsule (PLIC).
  • Diffusion tensor (DT) imaging and white matter tractography can identify the location of the PLIC in relation to the tumor and may be useful in planning the operative trajectory.
  • This result was compared with the location of the PLIC determined by a blinded radiologist with the use of DT imaging.
  • The utility of DT imaging in determining the surgical approach to a thalamic JPA, degree of resection, and neurological outcomes were all evaluated.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Diffusion Tensor Imaging / standards. Microsurgery. Thalamus / pathology. Thalamus / surgery


8. Klein O, Grignon Y, Civit T, Pinelli C, Auque J, Marchal JC: [Childhood diencephalic pilocytic astrocytoma. A review of seven observations]. Neurochirurgie; 2006 Feb;52(1):3-14
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Childhood diencephalic pilocytic astrocytoma. A review of seven observations].
  • BACKGROUND AND PURPOSE: Pilocytic astrocytoma (PA) is a WHO grade I tumor of the central nervous system mostly arising in children and young adults.
  • Surgical treatment has to cope with both the difficulties of deep location and eloquent area tumors.
  • Mean age at diagnosis was 108 months (9 years) (range: 4 month-18 years), median age was 111 months.
  • The delay in diagnosis ranged from 48 hours up to 6 years.
  • TREATMENT: a shunting procedure was performed in 3 patients, a direct surgical approach in 5 patients (gross total removal: 2; partial removal: 3) and one patient had only a biopsy.
  • Chemotherapy was delivered for 4 children.
  • We observed tumor regression in two patients at 1 and 17 years after the beginning of treatment.
  • Correct diagnosis was only made for two cases at the initial pathological examination.
  • Pathological diagnosis is sometimes difficult to assess.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Hypothalamic Neoplasms / surgery. Thalamic Diseases / surgery
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Dominance, Cerebral / physiology. Female. Follow-Up Studies. Humans. Hypothalamus / pathology. Hypothalamus / surgery. Infant. Magnetic Resonance Imaging. Male. Quality of Life. Radiotherapy, Adjuvant. Reoperation. Retrospective Studies. Survival Rate. Thalamus / pathology. Thalamus / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16609655.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Hadjipanayis CG, Kondziolka D, Gardner P, Niranjan A, Dagam S, Flickinger JC, Lunsford LD: Stereotactic radiosurgery for pilocytic astrocytomas when multimodal therapy is necessary. J Neurosurg; 2002 Jul;97(1):56-64
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for pilocytic astrocytomas when multimodal therapy is necessary.
  • OBJECT: The goal of this study was to examine the role of stereotactic radiosurgery in the treatment of patients with recurrent or unresectable pilocytic astrocytomas.
  • METHODS: During a 13-year interval, 37 patients (median age 14 years) required multimodal treatment of recurrent or unresectable pilocytic astrocytomas.
  • Diagnosis was confirmed with the aid of stereotactic biopsy in 12 patients, open biopsy in five, partial resection in eight, and near-total resection in 12.
  • Multimodal treatment included fractionated radiation therapy in 10 patients, stereotactic intracavitary irradiation of tumor in four, chemotherapy in two, cyst drainage in six, ventriculoperitoneal shunt placement in three, and additional cytoreductive surgery in four.
  • The median radiosurgical dose to the tumor margin was 15 Gy (range 9.6-22.5 Gy).
  • No procedure-related death was encountered.
  • Thirty-three (89%) of 37 patients are alive at a median follow-up period of 28 months after radiosurgery and 59 months after diagnosis.
  • CONCLUSIONS: Stereotactic radiosurgery is a valuable adjunctive strategy in the management of recurrent or unresectable pilocytic astrocytomas.
  • Despite the favorable histological characteristics and prognosis usually associated with this neoplasm, an adverse location, recurrence, or progression of this disease requires alternative therapeutic approaches such as radiosurgery.
  • [MeSH-major] Astrocytoma / surgery. Astrocytoma / therapy. Brain Stem Neoplasms / surgery. Brain Stem Neoplasms / therapy. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Biopsy. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Cysts / surgery. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Radiotherapy / adverse effects. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12134933.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Hsu TR, Wong TT, Chang FC, Ho DM, Tang RB, Thien PF, Chang KP: Responsiveness of progressive optic pathway tumors to cisplatin-based chemotherapy in children. Childs Nerv Syst; 2008 Dec;24(12):1457-61
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Responsiveness of progressive optic pathway tumors to cisplatin-based chemotherapy in children.
  • BACKGROUND: Though the pathology of optic pathway tumor is mostly pilocytic astrocytoma, the benign tumor behaves like malignant tumor because total resection is not feasible.
  • Adjuvant chemotherapy might be a reasonable strategy for management of these low grade tumors which keep growing.
  • We evaluate the responsiveness of optic pathway tumor to cisplatin-based chemotherapy.
  • METHODS: Patients with unresectable and progressive optic pathway tumors received conventional chemotherapy including cisplatin, etoposide, and vinblastine were enrolled in this study from 1992 to 2007.
  • Brain MRI was performed every 3 months to evaluate the objective response to chemotherapy.
  • The median age at diagnosis was 30 months old (range from 3 months to 11 years old).
  • The pathology showed pilocytic astrocytomas in 11 patients, astrocytoma in one patient, and anaplastic astrocytomas in two patients.
  • The toxicity of the cisplatin-based chemotherapy showed mild bone marrow suppression in 13 patients (81.3%), infection in nine patients (56.3%), gastrointestinal discomfort in seven patients (43.8%), renal insufficiency in two patient (12.5%), cerebral salt wasting syndrome with hyponatremia in one patient (6.25%) and high pitch hearing loss in two patients (12.5%).
  • CONCLUSION: Cisplatin-based chemotherapy is an effective regimen for control of progressive optic pathway tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Optic Nerve Neoplasms / drug therapy
  • [MeSH-minor] Bone Marrow Diseases / chemically induced. Child. Child, Preschool. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease-Free Survival. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Gastrointestinal Diseases / chemically induced. Humans. Infection / chemically induced. Magnetic Resonance Imaging. Male. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1961 Nov;49:322-31 [13923365.001]
  • [Cites] Neurosurgery. 1996 Jun;38(6):1114-8; discussion 1118-9 [8727140.001]
  • [Cites] J Neurosurg. 1993 Jul;79(1):32-5 [8315466.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 May;25(5):372-8 [12759623.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):51-5 [8455063.001]
  • [Cites] Cancer. 1980 Mar 15;45(6):1467-71 [7357527.001]
  • [Cites] Pediatr Neurosurg. 1993 Jul-Aug;19(4):186-95 [8329303.001]
  • [Cites] Br J Ophthalmol. 1969 Dec;53(12):793-8 [5386369.001]
  • [Cites] J Neurosurg. 1978 Jan;48(1):34-41 [412924.001]
  • [Cites] Neuro Oncol. 2000 Oct;2(4):213-20 [11265230.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):215-25 [8420869.001]
  • [Cites] Ann Neurol. 1999 Mar;45(3):393-6 [10072056.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Jun;11(6):1067-79 [3997589.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4209-16 [12377964.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):850-6 [8487049.001]
  • [Cites] Ann Neurol. 1997 Feb;41(2):143-9 [9029062.001]
  • [Cites] Acta Paediatr. 1993 Mar;82(3):327-8 [8495098.001]
  • [Cites] Br J Ophthalmol. 1986 Mar;70(3):179-82 [3082351.001]
  • [Cites] Pediatr Neurol. 2003 Apr;28(4):262-70 [12849878.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):661-7 [2213155.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4572-8 [14673044.001]
  • [Cites] Surv Ophthalmol. 1994 Mar-Apr;38(5):427-52 [8009427.001]
  • [Cites] Neurol Clin. 1991 Feb;9(1):163-77 [2011108.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):116-20 [12672283.001]
  • [Cites] Neurol Clin. 1991 May;9(2):467-77 [1944110.001]
  • [Cites] Arch Dis Child. 1997 Mar;76(3):259-63 [9135269.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):704-10 [11597812.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2156-67 [16220552.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):1051-9 [7842408.001]
  • [Cites] J Neurosurg. 1988 Jan;68(1):85-98 [3275755.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:143-6 [15662798.001]
  • [Cites] Oncology (Williston Park). 1989 Sep;3(9):23-30; discussion 34, 37-8 [2518324.001]
  • [Cites] Neurology. 1986 Sep;36(9):1173-8 [3748382.001]
  • (PMID = 18769928.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Huber J, Sovinz P, Lackner H, Mokry M, Eder H, Urban C: Diencephalic syndrome: a frequently delayed diagnosis in failure to thrive. Klin Padiatr; 2007 Mar-Apr;219(2):91-4
Genetic Alliance. consumer health - Diencephalic Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diencephalic syndrome: a frequently delayed diagnosis in failure to thrive.
  • Treatment options consist of surgical resection, radiation therapy (RT) and chemotherapy.
  • We describe the clinical course of two children suffering from diencephalic syndrome due to unresectable hypothalamic gliomas and emphasize the importance of chemotherapy as a first-line treatment.
  • PATIENTS AND METHODS: We report about two children, at the age of 21 months and 13 months at diagnosis, who presented with severe dystrophy at 12 months and 6 months respectively.
  • Imaging of the brain showed a suprasellar mass, identified histologically as low grade pilocytic astrocytoma.
  • Both patients were treated with chemotherapy which induced tumor regression and stable disease.
  • CONCLUSIONS: Diencephalic syndrome caused by a hypothalamic/chiasmatic astrocytoma is a rare cause of failure to thrive in children so that diagnosis is frequently delayed.
  • It should be considered as differential diagnosis in any child with dystrophy despite adequate caloric intake.
  • Since most of these tumors in that specific anatomic site are regarded to be unresectable, chemotherapy including carboplatin and vincristine may reveal clinical improvement in these patients.
  • [MeSH-major] Astrocytoma / diagnosis. Failure to Thrive / etiology. Hypothalamic Diseases / diagnosis. Hypothalamic Neoplasms / diagnosis. Optic Chiasm. Optic Nerve Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child, Preschool. Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Hydrocephalus / etiology. Infant. Neoplasm, Residual / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405074.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Lustig RH, Post SR, Srivannaboon K, Rose SR, Danish RK, Burghen GA, Xiong X, Wu S, Merchant TE: Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab; 2003 Feb;88(2):611-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for the development of obesity in children surviving brain tumors.
  • Hypothalamic obesity, a syndrome of intractable weight gain due to hypothalamic damage, is an uncommon but devastating complication for children surviving brain tumors.
  • We undertook a retrospective evaluation of the body mass index (BMI) curves for the St. Jude Children's Research Hospital brain tumor population diagnosed between 1965 and 1995 after completion of therapy to determine risk factors for the development of obesity.
  • Inclusion criteria were: diagnosis less than 14 yr of age, no spinal cord involvement, ambulatory, no supraphysiologic hydrocortisone therapy (>12 mg/m(2) x d), treatment and follow-up at St. Jude Children's Research Hospital, and disease-free survival greater than 5 yr (n = 148).
  • Risk factors examined were age at diagnosis, tumor location, histology, extent of surgery, hydrocephalus requiring ventriculoperitoneal shunting, initial high-dose glucocorticoids, cranial radiation therapy, radiation dosimetry to the hypothalamus, intrathecal chemotherapy, and presence of endocrinopathy.
  • Risk factors were: age at diagnosis (P = 0.04), radiation dosimetry to the hypothalamus (51-72 Gy, P = 0.002 even after hypothalamic and thalamic tumor exclusion), and presence of any endocrinopathy (P = 0.03).
  • In addition, risk factors when compared with BMI slope for the general American pediatric population included: tumor location (hypothalamic, P = 0.001), tumor histology (craniopharyngioma, P = 0.009; pilocytic astrocytoma, P = 0.043; medulloblastoma, P = 0.039); and extent of surgery (biopsy, P = 0.03; subtotal resection, P = 0.018).
  • These results verify hypothalamic damage, either due to tumor, surgery, or radiation, as the primary cause of obesity in survivors of childhood brain tumors.
  • In particular, hypothalamic radiation doses of more than 51 Gy are permissive.
  • These results reiterate the importance of the hypothalamus in energy balance, provide risk assessment criteria for preventative measures before the development of obesity in at-risk patients, and suggest therapeutic strategies to reduce the future development of obesity.
  • [MeSH-major] Brain Neoplasms / epidemiology. Craniopharyngioma / epidemiology. Obesity / epidemiology
  • [MeSH-minor] Astrocytoma / drug therapy. Astrocytoma / epidemiology. Astrocytoma / radiotherapy. Cerebellar Neoplasms / drug therapy. Cerebellar Neoplasms / epidemiology. Cerebellar Neoplasms / radiotherapy. Child. Child, Preschool. Disease-Free Survival. Humans. Hypothalamus / physiology. Medulloblastoma / drug therapy. Medulloblastoma / epidemiology. Medulloblastoma / radiotherapy. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12574189.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA023944; United States / NCI NIH HHS / CA / P30CA12765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


13. Gnekow AK, Kortmann RD, Pietsch T, Emser A: Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH). Klin Padiatr; 2004 Nov-Dec;216(6):331-42
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH).
  • Early radiotherapy (RT) shall be deferred by chemotherapy (CT) within the concept of the HIT-LGG 1996 study, offering a comprehensive treatment strategy for all age groups.
  • PATIENTS: 198 of 905 protocol patients (21.9 %) had a chiasmatic (34), chiasmatic-hypothalamic (144) or hypothalamic (20) primary tumor, median age at diagnosis 3.6 years (0.2-16.3 y.), 54 had neurofibromatosis (27.3 %), 108 female (54.5 %).
  • The initial neurosurgical intervention resulted in 5 complete, 26 subtotal, 45 partial resections, 67 biopsies; 55 children had a diagnosis on the basis of neuroradiologic findings.
  • Histology showed 132 pilocytic astrocytoma I degrees , 6 astrocytoma II degrees /nos and 2 DIGG/DIA I degrees (3 not known).
  • RESULTS: 82 children were treated at diagnosis, 68 upon clinical or radiological progression following observation times of 3.0 to 115.0 months.
  • At a median observation time of 50.1 months 21 tumors are stable, 3 regressive (2 not evaluable, 1 death).
  • At a median observation time of 44.7 months 2 children are in complete remission, 92 tumors are stable, 8 regressive, 9 progressive.
  • Within the CT-group children with an age at diagnosis < 1 year and non-pilocytic histology are at increased risk for early progression.
  • CONCLUSION: Within the comprehensive treatment strategy for low grade glioma HIT-LGG 1996 chemotherapy is effective to delay the need for early radiotherapy in chiasmatic-hypothalamic glioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Glioma / therapy. Hypothalamus. Optic Chiasm. Optic Nerve Neoplasms / therapy
  • [MeSH-minor] Adolescent. Age Factors. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Carboplatin / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Infant. Male. Radiotherapy Dosage. Time Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15565548.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


14. Walter AW, Gajjar A, Reardon DA, Thompson SJ, Langston JW, Jones-Wallace D, Kun LE, Heideman RL: Tamoxifen and carboplatin for children with low-grade gliomas: a pilot study at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol; 2000 May-Jun;22(3):247-51
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The authors conducted a single-arm, prospective study using tamoxifen and carboplatin for the treatment of children with progressive or symptomatic low-grade gliomas.
  • One patient was excluded after induction chemotherapy because of the diagnosis of a nonmalignant condition.
  • RESULTS: The median age at diagnosis was 5.3 years, the median age at initiation of chemotherapy was 8.3 years.
  • Eight patients had tumors of the hypothalamus/optic pathway, two patients had thalamic tumors, and one patient each had tumors in the temporal lobe, tectum, and brain stem.
  • Tumor histologic findings included fibrillary astrocytoma (n = 2), juvenile pilocytic astrocytoma (n = 6), and oligodendroglioma (n = 1).
  • The best response to therapy was a partial response in two patients, stable disease in nine patients, and progressive disease in two patients.
  • Tamoxifen and carboplatin chemotherapy did not result in a significant number of objective responses in children with low-grade gliomas.
  • Nonmyelosuppressive agents such as tamoxifen deserve additional evaluation in the treatment of children with low-grade gliomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Child. Child, Preschool. Disease Progression. Disease-Free Survival. Enzyme Inhibitors / administration & dosage. Female. Humans. Life Tables. Male. Prospective Studies. Protein Kinase C / antagonists & inhibitors. Survival Analysis. Survival Rate. Tamoxifen / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10864056.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA-20180; United States / NCI NIH HHS / CA / P01 CA-23099; United States / NCI NIH HHS / CA / P30 CA-21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 094ZI81Y45 / Tamoxifen; BG3F62OND5 / Carboplatin; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


15. Akay KM, Izci Y, Baysefer A, Atabey C, Kismet E, Timurkaynak E: Surgical outcomes of cerebellar tumors in children. Pediatr Neurosurg; 2004 Sep-Oct;40(5):220-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathological diagnoses were as follows: pilocytic astrocytoma (48.2%); medulloblastoma (22.2%); ependymoma (18.5%); fibrillary astrocytoma grade III (3.7%); cystic oligodendroglioma (3.7%), and hemangioblastoma (3.7%).
  • The total removal of pediatric cerebellar tumors without neurological deficit is possible with appropriate microsurgical techniques excluding brain stem invasion.
  • The follow-up periods must be shorter if brain stem invasion exists.
  • Radiotherapy and chemotherapy are the adjuvant therapies according to the pathological diagnosis and the patient's age.
  • [MeSH-major] Astrocytoma / surgery. Cerebellar Neoplasms / surgery. Ependymoma / surgery. Medulloblastoma / surgery
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Humans. Male. Neoplasm Invasiveness. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel.
  • (PMID = 15687736.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


16. Allen JC: Initial management of children with hypothalamic and thalamic tumors and the modifying role of neurofibromatosis-1. Pediatr Neurosurg; 2000 Mar;32(3):154-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Optic pathway/hypothalamus gliomas (OPG) arise primarily from a slower-growing juvenile pilocytic astrocytoma, and thalamic gliomas arise primarily from a fibrillary astrocytoma which can become clinically and histologically more aggressive.
  • The major therapeutic challenge for these patients is to maximize their quality of life by preserving visual and endocrine function while minimizing treatment-related morbidity.
  • Treatment is often initiated at diagnosis in infants and toddlers who have a major visual impairment or the diencephalic syndrome.
  • The judicious application of chemotherapy may serve to forestall the need for radiotherapy or surgery.
  • However, over 90% of children with OPG without NF-1 will require some form of therapy.
  • Current multimodality therapy is relatively ineffective.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Hypothalamic Neoplasms / surgery. Neurofibromatosis 1 / surgery. Thalamic Diseases / surgery
  • [MeSH-minor] Child. Child, Preschool. Humans. Hypothalamus / pathology. Infant. Magnetic Resonance Imaging. Neoadjuvant Therapy. Optic Nerve Glioma / diagnosis. Optic Nerve Glioma / surgery. Thalamus / pathology

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10867564.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 21
  •  go-up   go-down


17. Khaw SL, Coleman LT, Downie PA, Heath JA, Ashley DM: Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer; 2007 Nov;49(6):808-11
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROCEDURE: Eligible patients had had a diagnosis of low-grade glioma with or without histological confirmation.
  • Therapy was stopped on completion of the targeted 12 cycles of chemotherapy or on evidence of tumor progression.
  • Median age at diagnosis was 5.5 years (range 2.6-15.0 years) and at commencement of temozolomide treatment was 9.0 years (range 3.8-15.2 years).
  • Nine patients had a histological diagnosis of pilocytic astrocytoma.
  • A total of 111 cycles of therapy have been administered.
  • Median time to progression was 6.7 months (range 1.5-41.8 months).
  • Twelve of 13 patients remain alive at the time of report.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Spinal Cord Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17588234.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


18. Burzynski SR, Weaver RA, Lewy RI, Janicki TJ, Jurida GF, Szymkowski BG, Khan MI, Bestak M: Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report. Drugs R D; 2004;5(6):315-26
Hazardous Substances Data Bank. Glutamine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the response rates, survival and toxicity of treatment with antineoplaston A10 and AS2-1 (ANP) in the first 12 children enrolled in our studies diagnosed with incurable recurrent and progressive multicentric glioma.
  • Six patients were diagnosed with pilocytic astrocytoma, four with low-grade astrocytoma and one with astrocytoma grade 2.
  • The average duration of intravenous ANP therapy was 16 months and the average dosage of A10 was 7.95 g/kg/day and of AS2-1 was 0.33 g/kg/day.
  • Ten patients are alive and well from 2 to >14 years post-diagnosis.
  • CONCLUSION: The results of the present study are favourable in comparison with radiation therapy and chemotherapy.
  • We believe that confirmation of these results through further studies may introduce a new promising treatment for incurable paediatric brain tumours.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzeneacetamides / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Glutamine / analogs & derivatives. Glutamine / therapeutic use. Phenylacetates / therapeutic use. Piperidones / therapeutic use
  • [MeSH-minor] Adolescent. Astrocytoma / drug therapy. Astrocytoma / pathology. Child. Child, Preschool. Disease Progression. Drug Combinations. Drug Therapy, Combination. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / prevention & control. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15563234.001).
  • [ISSN] 1174-5886
  • [Journal-full-title] Drugs in R&D
  • [ISO-abbreviation] Drugs R D
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzeneacetamides; 0 / Drug Combinations; 0 / Phenylacetates; 0 / Piperidones; 0RH81L854J / Glutamine; 104624-98-8 / antineoplaston AS 2-1; 91531-30-5 / antineoplaston A10
  •  go-up   go-down


19. Salgado JV, Costa-Silva M, Malloy-Diniz LF, Siqueira JM, Teixeira AL: Prefrontal cognitive dysfunction following brainstem lesion. Clin Neurol Neurosurg; 2007 May;109(4):379-82
Hazardous Substances Data Bank. METHYLPHENIDATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 29-year-old man developed several cognitive and behavioral symptoms after neurosurgery for resection of a pilocytic astrocytoma in the pontine-mesencephalic area.
  • Interestingly, the cognitive symptoms improved after treatment with methylphenidate, which is a drug that modules catecholaminergic neurotransmission, thereby supporting this hypothesis.
  • [MeSH-major] Astrocytoma / surgery. Brain Stem Neoplasms / surgery. Cognition Disorders / physiopathology. Postoperative Complications / physiopathology. Prefrontal Cortex / physiopathology
  • [MeSH-minor] Adolescent. Adult. Attention / drug effects. Attention / physiology. Central Nervous System Stimulants / therapeutic use. Educational Status. Follow-Up Studies. Humans. Impulsive Behavior / diagnosis. Impulsive Behavior / drug therapy. Impulsive Behavior / physiopathology. Inhibition (Psychology). Interpersonal Relations. Learning Disorders / diagnosis. Learning Disorders / drug therapy. Learning Disorders / physiopathology. Male. Methylphenidate / therapeutic use. Neuropsychological Tests. Problem Solving / drug effects. Problem Solving / physiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17275997.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 207ZZ9QZ49 / Methylphenidate
  •  go-up   go-down


20. Liang CL, Lu K, Liliang PC, Chen HJ: Gamma Knife surgery for optic glioma. Report of 2 cases. J Neurosurg; 2010 Dec;113 Suppl:44-7
Genetic Alliance. consumer health - Glioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Optic pathway/hypothalamic gliomas represent approximately 2%-5% of brain tumors in children.
  • Total excision, subtotal excision, subtotal excision followed by irradiation, radiation therapy alone, chemotherapy, and no treatment at all have been reported.
  • The histological diagnosis was confirmed to be pilocytic astrocytoma in both cases.
  • Treatments were planned with the prescription of 11 Gy to the 50% isodose line for the optic chiasm glioma and 15 Gy to the 50% isodose line for the optic nerve glioma.
  • During the follow-up period, neither of the patients developed any endocrine dysfunction.
  • Gamma Knife surgery permits treatment of optic glioma with good tumor control and no clinically relevant morbidity.
  • With the ability to deliver a high dose to the tumor while sparing normal brain tissue, especially the optic nerve, optic chiasm, and pituitary gland, GKS should be the choice of treatment for optic gliomas.
  • [MeSH-major] Astrocytoma / surgery. Optic Nerve / surgery. Optic Nerve Glioma / surgery. Radiosurgery / instrumentation
  • [MeSH-minor] Adolescent. Child. Female. Humans. Magnetic Resonance Imaging. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21121786.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Stieber VW: Low-grade gliomas. Curr Treat Options Oncol; 2001 Dec;2(6):495-506
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Low-grade gliomas are uncommon primary brain tumors classified as histologic grades I or II in the World Health Organization (WHO) classification.
  • The most common variants are pilocytic and low-grade astrocytomas, oligodendrogliomas, and mixed oligo-astrocytomas located in the cerebral hemispheres.
  • Prognostic factors that predict progression-free and overall survival include young age, pilocytic histology, good Karnofsky performance status, gross total resection, lack of enhancement on imaging, and small preoperative tumor volumes.
  • Dexamethasone is given at an initial dosage of 4 mg given four times daily.
  • Depending upon the proximity of the tumor to eloquent brain, gross total resection may or may not be possible.
  • In these cases a stereotactic biopsy is required to provide the histologic diagnosis.
  • It may be considered for any pilocytic astrocytoma from which a biopsy has been performed.
  • Based on prospective randomized phase III trials, 50.4 Gy to 54 Gy of conventionally fractionated radiotherapy appears to be a safe and effective regimen with minimal neurotoxicity; 45 Gy may be adequate for biopsied pilocytic astrocytomas.
  • Currently, RTOG trial 98-02 is investigating the efficacy of postradiation PCV chemotherapy (procarbazine, CCNU, and vincristine) in the treatment of newly diagnosed unfavorable low-grade gliomas.
  • Other areas of investigation include Temozolomide chemotherapy and the association of 1p and 19q chromosomal deletions with prolonged survival in oligodendrogliomas and sensitivity to PCV chemotherapy.
  • Radiosurgery and/or experimental chemotherapy may provide some measure of local control in the recurrent disease setting.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology
  • [MeSH-minor] Adolescent. Adult. Anti-Inflammatory Agents / therapeutic use. Anticonvulsants / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Edema / drug therapy. Brain Edema / etiology. Chemotherapy, Adjuvant. Combined Modality Therapy. Cranial Irradiation. Craniotomy. Dexamethasone / therapeutic use. Epidemiologic Methods. Forecasting. Humans. Prognosis. Radiosurgery. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Seizures / drug therapy. Seizures / etiology. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1995 Apr;82(4):523-9 [7897510.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):6-14 [2354409.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):375-86 [10433931.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):103-12 [11285548.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1784-91 [8082081.001]
  • [Cites] Can J Neurol Sci. 1990 May;17(2):177-83 [2192788.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):152-8 [11465395.001]
  • [Cites] Surg Neurol. 1989 Nov;32(5):334-42 [2683164.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):291-8 [10802351.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):85-101 [9210055.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3129-40 [9294476.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9 [10571199.001]
  • [Cites] J Neurosurg. 1989 Jun;70(6):853-61 [2715812.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):141-51 [11465394.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):113-23 [11285549.001]
  • [Cites] Neurology. 1998 Oct;51(4):1140-5 [9781544.001]
  • [Cites] CA Cancer J Clin. 2001 May-Jun;51(3):153-87; quiz 189-92 [11577495.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]
  • [Cites] J Neurosurg. 1984 Oct;61(4):665-73 [6470776.001]
  • [Cites] Eur Neurol. 1985;24(1):23-32 [3881262.001]
  • [Cites] J Neurosurg. 1988 May;68(5):684-8 [3357029.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):6 [10735012.001]
  • [Cites] J Neurosurg. 1993 Jun;78(6):909-14 [8487073.001]
  • [Cites] Acta Chir Scand. 1951 Dec 13;102(4):316-9 [14914373.001]
  • [Cites] Prog Exp Tumor Res. 1985;29:210-8 [4070632.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):779-84 [10837964.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):152-62 [11285553.001]
  • [Cites] J Neurosurg. 1987 Aug;67(2):224-30 [3598683.001]
  • (PMID = 12057095.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Anticonvulsants; 7S5I7G3JQL / Dexamethasone
  • [Number-of-references] 57
  •  go-up   go-down


22. Hadjipanayis CG, Kondziolka D, Flickinger JC, Lunsford LD: The role of stereotactic radiosurgery for low-grade astrocytomas. Neurosurg Focus; 2003 May 15;14(5):e15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: During a 13-year interval, 49 patients underwent stereotactic radiosurgery as part of multimodal treatment of their recurrent or unresectable low-grade astrocytomas.
  • Thirty-seven of these patients (median age 14 years) harbored pilocytic astrocytomas and 12 patients harbored World Health Organization (WHO) Grade II fibrillary astrocytomas (median age 25 years).
  • Each diagnosis was confirmed with the aid of stereotactic biopsy sampling in 17 patients, open biopsy sampling in five, partial resection in 13, and near-total resection in 14.
  • Multimodal treatment included fractionated radiotherapy in 14 patients, stereotactic intracavitary irradiation in five, chemotherapy in two, cyst drainage in eight, ventriculoperitoneal shunt placement in five, and additional cytoreductive surgery in five.
  • The median radiosurgical dose to the tumor margin was 15 Gy (range 9.6-22.5 Gy).
  • No procedure-related death was encountered.
  • Forty-five of 49 patients are alive at a median follow-up period of 32 months after radiosurgery and 63 months after diagnosis.
  • CONCLUSIONS: Stereotactic radiosurgery is a potential alternative or adjunctive intervention in the management of selected patients with pilocytic or WHO Grade II fibrillary astrocytomas, usually performed for small-volume tumors in an attempt to avoid larger-field fractionated radiotherapy.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Radiosurgery / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15669811.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Hernáiz Driever P, von Hornstein S, Pietsch T, Kortmann R, Warmuth-Metz M, Emser A, Gnekow AK: Natural history and management of low-grade glioma in NF-1 children. J Neurooncol; 2010 Nov;100(2):199-207
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pediatric neurofibromatosis type 1 (NF-1) patients are prone to developing low-grade glioma (LGG).
  • The HIT-LGG study 1996 aimed to observe the natural history of pediatric LGG and to postpone irradiation in younger children by using carboplatinum and vincristine in case non-surgical treatment was required.
  • Neuroimaging only allowed diagnosis in 67 patients.
  • Histology revealed pilocytic astrocytoma WHO grade I in 38 of 42 biopsied patients.
  • Sixty-five (60%) patients received non-surgical treatment, either chemotherapy (n = 55) or irradiation (n = 10).
  • The overall survival rate of 96% after a median observation time of 5.25 years contrasts with an event free survival rate (EFS) of 0.24 at 5 years.
  • In the chemotherapy group, we observed a 5-year progression-free survival (PFS) rate of 0.73.
  • Chemotherapy yielded acceptable PFS.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / therapy. Glioma / mortality. Glioma / therapy. Neurofibromatosis 1 / mortality. Neurofibromatosis 1 / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Disease Progression. Disease-Free Survival. Female. Humans. Infant. Male. Neurosurgical Procedures. Radiotherapy. Risk Factors

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):38-44 [10469435.001]
  • [Cites] Neurology. 2004 Nov 23;63(10):1944-6 [15557519.001]
  • [Cites] J Neurosurg. 1997 May;86(5):747-54 [9126887.001]
  • [Cites] J Neurosurg. 1993 Jul;79(1):32-5 [8315466.001]
  • [Cites] Klin Padiatr. 2004 Nov-Dec;216(6):331-42 [15565548.001]
  • [Cites] Br J Cancer. 2006 Jul 17;95(2):233-8 [16786042.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):417-20 [10958550.001]
  • [Cites] Klin Padiatr. 2000 Jul-Aug;212(4):177-84 [10994547.001]
  • [Cites] Br J Radiol. 2001 Jan;74(877):24-31 [11227773.001]
  • [Cites] J Child Neurol. 2002 Aug;17(8):630-7; discussion 646-51 [12403562.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8588-95 [17875698.001]
  • [Cites] Arch Dis Child. 1998 May;78(5):408-12 [9659085.001]
  • [Cites] Ann Neurol. 1999 Mar;45(3):393-6 [10072056.001]
  • [Cites] Neurology. 2005 Feb 8;64(3):553-5 [15699396.001]
  • [Cites] Childs Nerv Syst. 2002 Feb;18(1-2):43-7 [11935243.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4209-16 [12377964.001]
  • [Cites] Neurology. 2006 Oct 24;67(8):1509-12 [17060590.001]
  • [Cites] Brain. 2003 Jan;126(Pt 1):152-60 [12477702.001]
  • [Cites] Curr Opin Neurol. 2004 Apr;17(2):101-5 [15021234.001]
  • [Cites] Oncologist. 2000;5(6):477-85 [11110599.001]
  • [Cites] Eur J Cancer. 2006 Aug;42(12):1807-16 [16809032.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):917-20 [11556548.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4572-8 [14673044.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2570-5 [16735710.001]
  • [Cites] AMA Arch Neurol Psychiatry. 1958 Jun;79(6):607-21 [13532071.001]
  • [Cites] Genet Epidemiol. 2001 Jan;20(1):75-86 [11119298.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):1051-9 [7842408.001]
  • [Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]
  • [Cites] Pediatr Neurosurg. 2000 Mar;32(3):154-62 [10867564.001]
  • [Cites] Childs Nerv Syst. 2006 Oct;22(10):1332-7 [16639629.001]
  • [Cites] Ann Neurol. 2007 Mar;61(3):189-98 [17387725.001]
  • [Cites] Neurology. 2003 Nov 25;61(10):1397-400 [14638962.001]
  • [Cites] J Neurosurg. 1995 Mar;82(3):418-29 [7861220.001]
  • (PMID = 20352473.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


24. Salmaggi A, Fariselli L, Milanesi I, Lamperti E, Silvani A, Bizzi A, Maccagnano E, Trevisan E, Laguzzi E, Rudà R, Boiardi A, Soffietti R, Associazione Italiana di Neuro-oncologia: Natural history and management of brainstem gliomas in adults. A retrospective Italian study. J Neurol; 2008 Feb;255(2):171-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 21 of the patients histology was obtained and in 20 it was informative (2 pilocytic astrocytoma, 9 low-grade astrocytoma, 8 anaplastic astrocytoma and 1 glioblastoma).
  • In all of the 9 patients who were investigated with MR spectroscopy, the Cho/NAA ratio was elevated at diagnosis.
  • In 8 of the patients, an initial watch and wait policy was adopted, while 24 were treated shortly after diagnosis with either radiotherapy alone [4] or radiotherapy and chemotherapy [20] (mostly temozolomide).
  • Only minor radiological responses were observed after treatments; in a significant proportion of patients (9 out of 15) clinical improvement during therapy occurred in the context of radiologically (MRI) stable disease.
  • Median overall survival time was of 59 months.
  • Investigation of putative prognostically relevant parameters showed that a short time between disease onset and diagnosis was related to a shorter survival.
  • Compared with literature data, our study confirms the clinical and radiological heterogeneity of adult brainstem gliomas and underscores the need for multicenter trials in order to assess the efficacy of treatments in these tumors.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / therapy. Glioma / pathology. Glioma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Brain / pathology. Disease Progression. Female. Fluorodeoxyglucose F18. Humans. Image Processing, Computer-Assisted. Italy. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Prognosis. Radiopharmaceuticals. Retrospective Studies. Spinal Cord / pathology. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2006 Feb;104(2 Suppl):108-14 [16506498.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):711-5 [11723378.001]
  • [Cites] Neurosurg Rev. 2005 Oct;28(4):330-2 [16001287.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1991;53:148-58 [1803873.001]
  • [Cites] Brain. 2001 Dec;124(Pt 12):2528-39 [11701605.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):20-31 [15850898.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):235-41 [8420871.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1266-72 [16525181.001]
  • [Cites] Neurology. 1998 Oct;51(4):1136-9 [9781543.001]
  • [Cites] Acta Neurochir (Wien). 1986;79(2-4):67-73 [3962745.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):133-9 [15565574.001]
  • [Cites] Neurochirurgie. 1989;35(1):41-6 [2654682.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):757-60 [2004952.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 18293027.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


25. Massimino M, Spreafico F, Riva D, Biassoni V, Poggi G, Solero C, Gandola L, Genitori L, Modena P, Simonetti F, Potepan P, Casanova M, Meazza C, Clerici CA, Catania S, Sardi I, Giangaspero F: A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J Neurooncol; 2010 Oct;100(1):65-71
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnoses were clinical in 13 cases and histological in 24, and comprised: pilocytic astrocytoma (17), ganglioglioma (3), pilomyxoid astrocytoma (2), and fibrillary astrocytoma (2).
  • Treatment was prompted by radiological evidence of progression and/or clinical deterioration a median 18 months after the first diagnosis.
  • After initial MRI staging, neurological and clinical examinations were performed before each chemotherapy cycle, with MRI after the first three courses and every three months thereafter.
  • After a median 48 months, a volume reduction was appreciable in 24 cases (65%) and response was maximum 12 months after starting treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Cisplatin / therapeutic use. Etoposide / therapeutic use. Glioma / drug therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols. Child. Child, Preschool. Disease-Free Survival. Drug Administration Schedule. Electroencephalography. Evoked Potentials, Visual / drug effects. Female. Humans. Infant. Infant, Newborn. Longitudinal Studies. Magnetic Resonance Imaging / methods. Male

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Child Neurol. 2008 Oct;23(10):1186-94 [18952585.001]
  • [Cites] Curr Opin Neurol. 2003 Dec;16(6):657-64 [14624073.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2792-9 [9256121.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Aug;25(8):644-8 [12902920.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):890-900 [17283119.001]
  • [Cites] J Neurosurg. 2007 May;106(5 Suppl):354-62 [17566201.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):544-53; discussion 554-5 [12943571.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):586-96 [16411210.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4209-16 [12377964.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):245-50 [18386785.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):850-6 [8487049.001]
  • [Cites] J Neurooncol. 2009 Mar;92(1):49-56 [19005618.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):67-71 [7782852.001]
  • [Cites] N Engl J Med. 2009 May 21;360(21):2248; author reply 2249 [19458374.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2636-42 [15861409.001]
  • [Cites] Acta Neuropathol. 2009 Sep;118(3):401-5 [19543740.001]
  • [Cites] Strahlenther Onkol. 2002 Jan;178(1):10-7 [11977386.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4572-8 [14673044.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1335-42 [18548091.001]
  • [Cites] Acta Neuropathol. 2009 Jun;117(6):657-65 [19271226.001]
  • [Cites] Med Pediatr Oncol. 1991;19(4):295-300 [2056973.001]
  • [Cites] J Neurosurg. 1991 May;74(5):701-8 [1901597.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):569-77 [10080601.001]
  • [Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]
  • (PMID = 20151174.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Lesniak MS, Klem JM, Weingart J, Carson BS Sr: Surgical outcome following resection of contrast-enhanced pediatric brainstem gliomas. Pediatr Neurosurg; 2003 Dec;39(6):314-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We retrospectively reviewed the charts of all pediatric patients admitted to the Johns Hopkins Hospital with a diagnosis of a brainstem tumor between January 1985 and December 2000.
  • Fifty-seven patients (64.0%) underwent surgical resection while 32 (36%) were treated with radiation and/or chemotherapy.
  • The pathology was consistent with juvenile pilocytic astrocytoma in 30 patients (52.6%) and glioblastoma multiforme in 12 patients (21.1%).
  • Consequently, we recommend surgical resection and pathological diagnosis of all enhancing brainstem tumors with adjuvant therapy reserved for recurrent or unresectable cases.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / surgery. Glioma / pathology. Glioma / surgery. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Contrast Media / administration & dosage. Female. Humans. Infant. Male. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Sensitivity and Specificity. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • [CommentIn] Pediatr Neurosurg. 2004 Mar-Apr;40(2):99; author reply 100 [15292646.001]
  • (PMID = 14734866.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down






Advertisement